

Valeant Pharmaceuticals International, Inc.  
Form DEFA14A  
March 21, 2018

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
SCHEDULE 14A INFORMATION  
Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934

Filed by the Registrant    Filed by a Party other than the Registrant  
Check the appropriate box:  
Preliminary Proxy Statement  
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  
Definitive Proxy Statement  
Definitive Additional Materials  
Soliciting Material Pursuant to § 240.14a-12

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.  
(Name of Registrant as Specified In Its Charter)  
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)  
No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



\*\*\* Exercise Your *Right* to Vote \*\*\*

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on April 30, 2018.

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.  
ATTN: CHRISTINA M. ACKERMANN  
2150 SAINT ELZEAR BLVD. WEST  
LAVAL, QUEBEC H7L 4A8  
CANADA

**Meeting Information**

**Meeting Type:** Annual Meeting  
**For holders as of:** March 5, 2018  
**Date:** April 30,  
2018      **Time:** 9:00 a.m.  
(local time)  
**Location:** 2150 Saint Elzear Blvd. West  
Laval, Quebec H7L 4A8 Canada

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at [www.proxyvote.com](http://www.proxyvote.com) or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

**See the reverse side of this notice to obtain proxy materials and voting instructions.**

— Before You Vote —

### How to Access the Proxy Materials

#### **Proxy Materials Available to VIEW or RECEIVE:**

Notice of Annual Meeting of Shareholders and  
Management Proxy Circular and Proxy Statement  
Annual Report

#### **How to View Online:**

Have the information that is printed in the box  
marked by the arrow (located on the following page)  
and visit: [www.proxyvote.com](http://www.proxyvote.com).

#### **How to Request and Receive a PAPER or E-MAIL Copy:**

If you want to receive a paper or e-mail copy of these  
documents, you must request one. There is NO  
charge for requesting a copy. Please choose one of  
the following methods to make your request:

- 1) *BY INTERNET*: [www.proxyvote.com](http://www.proxyvote.com)
- 2) *BY TELEPHONE*: 1-800-579-1639
- 3) *BY E-MAIL*\*: [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com)

\* If requesting materials by e-mail, please send a  
blank e-mail with the information that is printed in  
the box marked by the arrow (located on the  
following page) in the subject line.

Requests, instructions and other inquiries sent to this  
e-mail address will NOT be forwarded to your  
investment advisor.

Please make the request as instructed above on or  
before April 16, 2018 to facilitate timely delivery.

— How To Vote —

#### Please Choose One of the Following Voting Methods

**Vote In Person:** Many shareholder meetings have attendance requirements including, but not limited to, the  
possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form DEFA14A

special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

**Vote By Internet:** To vote now by Internet, go to *www.proxyvote.com*. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.

**Vote By Mail:** You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

## Voting Items

**The Board of Directors recommends you vote FOR proposals 1, 2, 3 and 4 below.**

1. Election of Directors

1a. Richard U. DeSchutter

1b. D. Robert Hale

1c. Dr. Argeris (Jerry) N.  
Karabelas

1d. Sarah B. Kavanagh

1e. Joseph C. Papa

1f. John A. Paulson

1g. Robert N. Power

1h. Russel C. Robertson

1i. Thomas W. Ross, Sr.

1j. Amy B. Wechsler, M.D.

2. The approval, in an advisory resolution, of the compensation of our Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.

3. The approval of an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of Common Shares authorized under such plan.

4. To appoint PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2019 Annual Meeting of Shareholders and to authorize the Company's Board of Directors to fix the auditors' remuneration.

Without limiting the general powers hereby conferred, the undersigned hereby directs the proxyholder to vote the Common Shares represented by this proxy in the manner set forth above.

